To halt brain diseases, drugs take aim at protein traffic jams that kill neurons
Elie Dolgin • Jan 16, 2019
Compound that normalizes flow of proteins in cells will now be tested in a clinical trial for ALS
Continue reading at Science Magazine.
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
FDA panel’s green light on glaucoma wearable device offers hope in sight.